Raaid Museitif, MD
Interventional Cardiology · Kenosha, WINPI 1992974174
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $53,425 of the $70,944 with a category attached, or 75.3%. Pfizer accounts for 83.3% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2019 at $32,715 and has fallen 94.1% since, to $1,918 in 2025. Among interventional cardiology clinicians in WI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 454 payments — averaging $156.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$59K
- Medtronic$4K
- Edwards Lifesciences$2K
- AstraZeneca$926
- E.r. Squibb & Sons, L.L.C.$631
- Novo Nordisk$624
- plus $4K from 26 others
What the payments were for
- Speaking & faculty fees$53,42575%
- Travel & lodging$6,5229%
- Food & beverage$10,88315%
- Education$1140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 87 | $59,120 |
| Medtronic | 34 | $3,565 |
| Edwards Lifesciences | 9 | $1,807 |
| AstraZeneca | 39 | $926 |
| E.r. Squibb & Sons, L.L.C. | 71 | $631 |
| Novo Nordisk | 30 | $624 |
| Boston Scientific | 7 | $601 |
| Johnson & Johnson | 32 | $561 |
| Novartis | 25 | $533 |
| Boehringer Ingelheim | 30 | $492 |
| Amgen | 16 | $281 |
| Heartflow, Inc. | 15 | $237 |
| Biotronik Inc. | 5 | $230 |
| Kestra Medical Technology Services, Inc. | 7 | $198 |
| Sanofi-aventis U.S. LLC | 8 | $133 |
| Lundbeck LLC | 8 | $131 |
| United Therapeutics Corporation | 1 | $115 |
| Bard Peripheral Vascular, Inc. | 1 | $111 |
| Aimmune Therapeutics, Inc. | 4 | $105 |
| Alnylam Pharmaceuticals Inc. | 4 | $83 |
| Penumbra, Inc. | 1 | $74 |
| AbbVie(2 entities) | 3 | $64 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $60 |
| Amarin Pharma, Inc. | 3 | $59 |
| Lilly USA, LLC | 3 | $55 |
| Abbott | 1 | $43 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| CSL Behring | 1 | $23 |
| Scpharmaceuticals Inc. | 1 | $22 |
| Impulse Dynamics (USA) Inc. | 1 | $19 |
| Atricure, Inc. | 1 | $13 |
| Bardy Diagnostics, Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELIQUIS$57,669
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,356
- Micra$267
- COREVALVE EVOLUT R$265
- SAPIEN 3 Ultra RESILIA$221
- CoreValve Evolut$193
- Rotablator Rotational Atherectomy System Console Kit$181
- OPTICROSS$166
- TEZSPIRE$125
- BREZTRI$125
- XARELTO$116
- TYVASO$115
- REMODULIN$115
- ORENITRAM$115
- Valiant Captivia$113
- LUTONIX$111
- Watchman$109
How this compares
$70,944 in reported general payments places this provider in the 90th percentile of 118 interventional cardiology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 412 | $425,152 |
| XareltoRivaroxaban | 29 | $45,804 |
| EntrestoSacubitril/Valsartan | 30 | $31,931 |
| BrilintaTicagrelor | 26 | $13,277 |
| Dofetilide | 19 | $5,472 |
| Ezetimibe | 192 | $4,377 |
| Metoprolol Succinate | 391 | $3,558 |
| ClopidogrelClopidogrel Bisulfate | 275 | $3,287 |
| Atorvastatin Calcium | 351 | $2,794 |
| Carvedilol | 297 | $2,646 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 116 | $1,973 |
| Losartan Potassium | 234 | $1,665 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 47 | $1,218 |
| Metoprolol Tartrate | 155 | $1,131 |
| Rosuvastatin Calcium | 192 | $1,072 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $59,120 | $425,152412 claims |
| Johnson & JohnsonXarelto | $561 | $45,80429 claims |
| NovartisEntresto | $533 | $31,93130 claims |
| AstraZenecaBrilinta | $926 | $13,27726 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 118 interventional cardiology providers in Wisconsin.
Other interventional cardiology in Kenosha
- Michael SalingerMilwaukee$216K
- Arun KalyanasundaramMarshfield$201K
- Michael RosenbergManitowoc$111K
- Tanvir BajwaMilwaukee$106K
- Suhail AllaqabandMilwaukee$88K
- Saif AnwaruddinMilwaukee$80K
- Iyad AzzamMilwaukee$60K
- Mark HoffmannWausau$52K
- Montoya TaylorMilwaukee$48K
- Sanjay SinghWaukesha$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.